Requests the FDA to modify the Prescribing Information for TRYPTRYR (acoltremon ophthalmic solution) to conform to requirements of CFR 201.57(c)(2)(iv) and to state: “indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye)“
🏛 Food and Drug Administration (FDA)FDA-2025-P-5790
Documents
0
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
No documents mirrored for this docket yet.